Combined oral immunotherapy shows lasting effect against peanut allergy four years later

In a report of the long-term outcomes of probiotics plus peanut oral immunotherapy, more than half of study participants were able to continue eating peanuts up to four years later.


Much attention has been paid to the potential of oral immunotherapy to treat food allergies. However, little is known about its long-term effects.

In a study in the Lancet Child & Adolescent Health (online, 15 August 2017), researchers followed up 56 people who had taken part in a placebo-controlled randomised trial of combined probiotic and peanut oral immunotherapy (PPOIT) for peanut allergy after a mean of 4.2 years[1]

They found that 16 (67%) of 24 participants who received PPOIT were still eating peanuts compared with only one (4%) of participants who received placebo. And following a food challenge, seven (58%) of 12 immunotherapy-treated participants showed sustained unresponsiveness at eight weeks compared with only 1 (7%) of 15 participants from the placebo group.

The researchers say the findings support the long-term clinical benefit of combined oral immunotherapy for peanut allergy and suggest that sustained unresponsiveness is a realistic goal for food allergy treatment.


[1] Hsiao K-C, Ponsonby A-L, Axelrad C et al. Long-term clinical and immunological effects of probiotic and peanut oral immunotherapy after treatment cessation: 4-year follow-up of a randomised, double-blind, placebo-controlled trial. Lancet Child Adolesc Health 2017. doi: 10.1016/S2352-4642(17)30041-X

Last updated
Clinical Pharmacist, CP, November 2017, Vol 9, No 11;9(11):DOI:10.1211/PJ.2017.20203684

You may also be interested in